60
The biosimilar balance is very good: But that wasn’t good enough for politicians. In 2019, the G-BA was commissioned with the Act for More Safety in the Supply of Medicines (GSAV) to initiate the automatic substitution of biotechnologically produced medicines in pharmacies . With the GKV Financial Stabilization Act it became concrete in 2022: It should initially…
Those